MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- INDOCO REMEDIES
INDOCO REMEDIES Share Price (INDOCO)
Here is the latest stock price and chart of Indoco Remedies. For more details, see the Indoco Remedies company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.
Mega Webinar on Jan 29th: Will 2021 be a boom or bust?
| Live BSE Quotes | Jan 22, 2021 (Close) | ||
|---|---|---|---|
| Price (Rs)317.20 | Open (Rs) 320.00 | High (Rs) 320.40 | Low (Rs) 311.20 |
| % Change-0.83 | Volume 8,015 | Value (Rs) 2,547,986 | 52-Week H/L 335.55 / 145.50 |
| Live NSE Quotes | Jan 22, 2021 (Close) | ||
|---|---|---|---|
| Price (Rs)317.30 | Open (Rs) 320.00 | High (Rs) 322.10 | Low (Rs) 311.00 |
| % Change-1.03 | Volume 176,248 | Value (Rs) 55,923,490 | 52-Week H/L 335.80 / 144.75 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -0.83% | 1 Month 13.61% | 3 Months 22.42% | 1 Year 39.40% | 5 Years (CAGR)* 0.98% | 10 Years (CAGR)* 17.93% |
* Compound Annual Growth Rate
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 4.26 | P/E Ratio (x) 74.47 | Market Cap (Rs m) 29,237.91 | P/BV (x) 4.33 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
INDOCO REMEDIES Share Price Today:
INDOCO REMEDIES last traded price was down 0.8% to Rs 317.2 on the BSE. On the NSE, INDOCO REMEDIES last traded price was down 1.0% to Rs 317.3. The total volume of shares traded was 0.2 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 1.2%. And the benchmark S&P BSE SENSEX was at 48,878.5 (down 1.5%).
Over the last 30 days, the INDOCO REMEDIES share price is up 17.9%. And over the last one year, INDOCO REMEDIES share price is up 38.2%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Crucial Week Ahead for the Indian Stock Market(Momentum Moves)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Related Views On News
INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)
Jan 27, 2020 | Updated on Jan 27, 2020For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)
Nov 5, 2019 | Updated on Nov 5, 2019For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)
Mar 28, 2019 | Updated on Mar 28, 2019Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.
More Views on NewsMost Popular
Why Gold Hit Lower Circuit (Fast Profits Daily)
Jan 11, 2021Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Time to Book Profits in Pharma Stocks (Fast Profits Daily)
Jan 15, 2021In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
A Rare Chance to Invest in Potential Multibaggers in 2021 (Profit Hunter)
Jan 11, 2021Our ace stock picker is ready to capitalise on a big growth opportunity.
Smallcap Stocks: Your Best Bet for 2021 and Beyond (Profit Hunter)
Jan 15, 2021The pandemic failed to thwart Richa's investing success formula for 2020.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK INDOCO REMEDIES
- Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON INDOCO REMEDIES
INDOCO REMEDIES - TIL COMPARISON
COMPARE INDOCO REMEDIES WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.